
Claims

1. Use of an antibody-drug conjugate in the manufacture of a medicament for treating a metastatic brain tumor,

wherein the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula is conjugated to an antibody via a thioether bond:



wherein A represents a connecting position to the antibody;

and wherein the antibody is an anti-HER2 antibody comprising a heavy chain consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of amino acid residues 1 to 214 of SEQ ID NO: 2, or

wherein the antibody is an anti-HER2 antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain

consisting of an amino acid sequence represented by SEQ ID NO: 2.

2. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is at least one selected from the group consisting of breast cancer, lung cancer, melanoma, renal cell cancer, kidney cancer, colorectal cancer, gastric cancer, head and neck cancer, hepatocellular cancer, liver cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic cancer, endometrial cancer, thyroid cancer, malignant lymphoma and sarcoma.

3. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is at least one selected from the group consisting of breast cancer, lung cancer and melanoma.

4. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is breast cancer.

5. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is lung cancer.

6. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is melanoma.

7. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is gastric cancer.

8. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is colorectal cancer.

9. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is bladder cancer.

10. Use according to claim 1, wherein the primary cancer for the metastatic brain tumor is sarcoma.

11. Use according to any one of claims 1 to 10, wherein the anti-HER2 antibody comprises a heavy chain consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.

12. Use according to any one of claims 1 to 10, wherein the anti-HER2 antibody comprises a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.

13. Use according to any one of claims 1 to 12, wherein the average number of units of the drug-linker conjugated

per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.